A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

a study on Lymphoma Non-Hodgkin Lymphoma

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Santa Monica, California and other locations
Dates
study started
study ends around

Description

Summary

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Official Title

A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Keywords

Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, B-Cell Lymphoma, TORL-5-700, TORL-5-700 at MTD/RP2D, TORL-5-700 at MTD/RP2D in combination with another agent, Monotherapy Expansion

Eligibility

You can join if…

Open to people ages 18 years and up

  • Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
  • Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
  • At least 1 measurable lesion per Lugano criteria.
  • Tumor tissue is available.
  • Adequate organ function

You CAN'T join if...

  • T-cell lymphoma
  • CLL or SL
  • Burkitt lymphoma and high-grade B-cell lymphoma
  • CNS involvement
  • Peripheral neuropathy > Grade 2
  • Uncontrolled medical conditions
  • Viral infections

Locations

  • UCLA accepting new patients
    Santa Monica California 90404 United States
  • Stanford University accepting new patients
    Stanford California 94305 United States
  • Sarah Cannon Research Institute accepting new patients
    Nashville Tennessee 37203 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
TORL Biotherapeutics, LLC
Links
Sign up for this study
ID
NCT07439653
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 155 study participants
Last Updated
Contact us about this trial